Metformin: The First-Line Tablet for Type 2 Diabetes
Metformin is the preferred initial oral medication for type 2 diabetes and should be started at 500-850 mg once or twice daily with meals, then titrated up to a maximum of 2000-2550 mg daily based on glycemic response and tolerability. 1, 2, 3, 4, 5, 3, 5, 6
Why Metformin First
Metformin has earned its position as first-line therapy through decades of evidence demonstrating:
- Cardiovascular benefit: Reduces risk of myocardial infarction and cardiovascular mortality compared to other agents 1, 2
- Weight neutrality or modest weight loss: Does not cause weight gain like sulfonylureas or insulin 2, 7
- Low hypoglycemia risk: Minimal risk when used alone 2, 7
- Cost-effectiveness: Inexpensive and widely available 2, 3
- Favorable lipid effects: Decreases LDL cholesterol and triglycerides 2
Practical Dosing Strategy
Start metformin at a low dose to minimize gastrointestinal side effects (nausea, diarrhea, abdominal discomfort):
- Initial dose: 500 mg once daily with dinner, or 850 mg once daily
- Titration: Increase by 500 mg weekly or 850 mg every 2 weeks as tolerated
- Target dose: 1000 mg twice daily (2000 mg total) is typically effective
- Maximum dose: 2550 mg daily, though maximal glucose-lowering often achieved at ~50% of maximum dose 3
Extended-release formulations may improve gastrointestinal tolerability if standard metformin is not tolerated 3.
Critical Contraindications
Do not use metformin if:
- eGFR <30 mL/min/1.73 m² (absolute contraindication) 3, 4
- Do not initiate if eGFR <45 mL/min/1.73 m² 4
- Reduce dose if eGFR 30-45 mL/min/1.73 m² 4
- Acute kidney injury, severe liver disease, alcohol abuse, heart failure with hemodynamic instability, or conditions predisposing to lactic acidosis 2, 4
When Metformin Alone Is Insufficient
If HbA1c remains ≥1.5% above target after 3 months on metformin, add a second agent 3, 5, 3. The choice depends on comorbidities:
For patients with established cardiovascular disease, heart failure, or chronic kidney disease:
- Add SGLT2 inhibitor (empagliflozin, canagliflozin, dapagliflozin) OR
- Add GLP-1 receptor agonist (semaglutide, dulaglutide, liraglutide)
- These agents reduce cardiovascular events, heart failure hospitalizations, and kidney disease progression by 12-39% 5, 8
For patients without cardiovascular/kidney disease:
- Sulfonylurea (glipizide, glyburide): Cheapest option but causes weight gain and hypoglycemia 2, 6
- DPP-4 inhibitor (sitagliptin, linagliptin): Weight neutral, low hypoglycemia risk 3, 6
- SGLT2 inhibitor or GLP-1 RA: Preferred if weight loss desired 3, 5
- Thiazolidinedione (pioglitazone): Effective but causes weight gain, edema, fracture risk 1, 7
Special Situations Requiring Immediate Insulin
Start insulin (with or without metformin) if:
- Blood glucose ≥300 mg/dL (16.7 mmol/L) OR HbA1c ≥10% (86 mmol/mol) 3, 5
- Evidence of catabolism: weight loss, ketosis, hypertriglyceridemia 3
- Markedly symptomatic hyperglycemia 1
Important Monitoring
- Vitamin B12 levels: Check periodically, as long-term metformin use causes biochemical B12 deficiency in some patients, potentially worsening neuropathy 3
- HbA1c: Recheck every 3 months and intensify therapy if not at individualized target 5
- Kidney function: Monitor eGFR at least annually 4
Common Pitfall to Avoid
Therapeutic inertia kills: Do not delay adding a second agent or insulin if metformin monotherapy fails to achieve glycemic targets after 3 months 5. The progressive nature of type 2 diabetes means most patients will eventually require combination therapy or insulin—this is expected disease progression, not treatment failure 1.